利巴韦林
帕利珠单抗
医学
流行病学
呼吸系统
重症监护医学
病毒
肽
病毒学
生物
内科学
丙型肝炎病毒
生物化学
作者
Анна А. Штро,Galina Petukhova,Aleksandra S. Romanova
出处
期刊:Molecules
[MDPI AG]
日期:2022-03-31
卷期号:27 (7): 2263-2263
被引量:3
标识
DOI:10.3390/molecules27072263
摘要
Respiratory syncytial virus infection (RSVI) is an acute medical and social problem in many countries globally. Infection is most dangerous for infants under one year old and the elderly. Despite its epidemiological relevance, only two drugs are registered for clinical use against RSVI: ribavirin (approved in a limited number of countries due to side effects) and palivizumab (Synagis), which is intended only for the prevention, but not the treatment, of infection. Currently, various research groups are searching for new drugs against RSV, with three main areas of research: small molecules, polymeric drugs (proteins and peptides), and plant extracts. This review is devoted to currently developed protein and peptide anti-RSV drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI